Harnessing Viral Specific Immunity for Fighting Cancer
Bridging the immunotherapy gap
Immunotherapy revolutionized cancer treatment, with over 40 products available and annual sales worth over 190 billion USD, providing patients with a variety of novel options
Immunotherapy market size, 2021-2031 (US$B)
However, these treatments suffer from low response rate, only 20% of the patients respond to today’s immunotherapies, on average
TROJAN – AI DRIVEN ANTIBODIES PLATFORM
Offers a promising solution for combating a wide range of cancer types
Trojan Bi-specific antibody is composed of 2 modules - Cancer targeting module and a Viral immunity activation module
Targets cancer cells and label them as virally infected cells
Harnessing the powerful anti-viral immunity to fight a variety of cancers.
VERSATILE
Switchable targeting arms and viral moieties, to attack different tumors
POWERFUL
Harnessing the power of viral immunity to fight cancer